Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Recombinant newcastle disease virus

A technology of virus and RNA virus, applied in the fields of DNA, paramyxovirus, prevention or treatment of tumor diseases, cancer treatment, negative-strand RNA virus, Newcastle disease virus, and genetically processed viruses, can solve problems such as not being constructed

Inactive Publication Date: 2007-10-17
BAYER SCHERING PHARMA OY
View PDF12 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These recombinant NDVs have not been constructed for the treatment of human diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant newcastle disease virus
  • Recombinant newcastle disease virus
  • Recombinant newcastle disease virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] Virus

[0021] The present invention relates generally to RNA viruses, preferably negative-strand RNA viruses, and more preferably to those viruses which have oncolytic properties and which can be genetically engineered. These viruses are:

[0022] - Paramyxovirus, preferably Newcastle disease virus (NDV), measles virus, mumps virus, Sendai virus;

[0023] - an orthomyxovirus, preferably an influenza virus;

[0024] - a baculovirus, preferably a vesicular stomatitis virus.

[0025] The subject of the present invention is therefore a recombinant oncolytic RNA virus comprising a nucleic acid with at least one transgene encoding a binding protein that is therapeutically active when expressed by virus-infected tumor cells .

[0026] Another subject of the present invention is a recombinant oncolytic RNA virus comprising a nucleic acid with at least one transgene encoding a prodrug converting enzyme expressed by tumor cells infected with the virus When it is therapeutic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.

Description

[0001] introduction [0002] The present invention relates to a recombinant RNA virus, preferably a paramyxovirus, preferably a Newcastle disease virus (NDV), for use in the treatment of diseases, in particular for oncolytic tumor therapy. The resulting recombinant virus encodes binding proteins (antibodies, ankyrin repeat molecules, peptides, etc.), prodrug converting enzymes and / or proteases and results in the selective expression of these molecules in virus-infected tumor cells. The activities of these binding proteins, prodrug converting enzymes and / or proteases all enhance the antitumor effect of the virus. The invention also describes the production of these modified viruses and their use for cancer therapy. Background technique [0003] Newcastle disease virus [0004] Chiocca (2002) reviewed oncolytic viruses commonly used in tumor therapy. Newcastle disease virus has been used as an experimental therapeutic for more than 40 years, as reviewed by Sinkovics and Horva...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/76C07K14/115
CPCA61K39/395A01K67/0271A61K8/35A01K2267/0331A61K35/768A61K8/37A61K38/47A61K8/4953A61K38/1709A61Q19/08C07K14/005C12N2760/18143C12N2760/18122A61K8/922A61K8/97A61K38/2013C12N2760/18132A61K8/99A61K8/34C07K2319/33A61P35/00A61K2300/00C12N7/00A61K35/76
Inventor 鲁道夫·拜尔弗洛里安·普勒尔克劳斯·博斯勒特汉斯·约尔格·维尔鲁达
Owner BAYER SCHERING PHARMA OY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com